Publications Poster (IOVC 2019): ParvOryx02: A Phase II Trial of Intravenous and Intratumoral Administration of H-1 Parvovirus in Patients with Metastatic Pancreatic CancerAbstract (CIMT 2018): High rate of objective anti-tumor response in 9 patients with primary or recurrent glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacizumab and PD-1 checkpoint blockadePaper (Molecular Therapy Journal, 2017): Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial Poster (ASCO 2015): Vaccination of MSI-H colorectal cancer patients with frameshift peptide antigens: A phase I/IIa clinical trial (MicOryx) Abstract (ASCO 2015): Vaccination of MSI-H colorectal cancer patients with frameshift peptide antigens: A phase I/IIa clinical trial (MicOryx)Poster (ASCO 2014): First combined intravenous and intracerebral application of an oncolytic virus, parvovirus h-1, in a Phase I/IIa clinical trial in patients with recurrent glioblastoma multiforme (ParvOryx) Poster (ASCO 2014): Phase I/IIa study of therapeutic p16INK4a vaccination in patients with HPV-associated cancers (VicOryx) Abstract (ASCO 2014): Vaccination of MSI-H colorectal cancer patients with frameshift peptide antigens – a Phase I/IIa clinical trial (MicOryx)